Shingles Vaccine Market Share to Touch 7.4% CAGR by 2030 with Top Key Players: GlaxoSmithKline Plc.,and Merck

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. Vaccination is one of the most effective ways to prevent diseases. A vaccine helps the body’s immune system to recognize and fight pathogens like viruses or bacteria, which then keeps us safe from the diseases they cause. Vaccines are made using the disease-causing virus or bacteria, but in a form that will not harm human body.


New York, NY -- (SBWire) -- 02/12/2020 --Shingles Vaccine Market is estimated to be valued at ~US$ 1,999.5 million in 2019. It is anticipated to further grow at a CAGR of ~7.4% from 2019 to 2030.

Leading Key Players:

GlaxoSmithKline plc.and Merck & Co.,Inc

Get Access Free To Sample Pages:

Shingles is an infectious disease which is caused by the reactivation of the chickenpox virus or herpes zoster. The common symptoms associated with this infection are development of rashes, ulcers blister and redness on the skin; exhaustion, and itching among others. Vaccines available for the treatment of shingles are Zostavax and Shingrix, which are manufactured by Merck & Co., Inc., & GlaxoSmithKline plc respectively.

By Product:

By Patient Type:
-Pediatric Patients
-Adult Patients

By Application:

-Under 50 Years Old
-50-60 Years Old
-60-70 Years Old
-Above 70 Years Old

By Region:
-North America
-Asia Pacific
-Rest of the World (ROW)

The sales growth of Shingrix vaccine has been especially notable since the time of its launch. Zostavax, manufactured by Merck was initially manufactured as a live vaccine in 2016, but the launch of Shingrix vaccine by GSK in October 2017, gained immense popularity. Shingrix, owing to its recombinant nature can be administered among a wide range of population, unlike the Zostavax. Moreover, admiration of Shingrix vaccine exhibited an effectiveness of approximately 90%.

Free Customization on Report:

The growing adoption of shingles vaccine can be attributed to greater level of protection offered by these vaccines as compared to other modes of treatment. Moreover, in the U.S., recommendation of shingles vaccine by federal health officials for individuals above the age of 50, has been crucial in incrementing its demand in the region.

The Shingles Vaccine market report answers important questions which include:
-Which regulatory authorities have granted approval to the application of Shingles Vaccine in HealthCare industry?
-How will the global Shingles Vaccine market grow over the forecast period?
-Which end use industry is set to become the leading consumer of Shingles Vaccine by 2030?
-What manufacturing techniques are involved in the production of the Shingles Vaccine?
-Which regions are the Shingles Vaccine market players targeting to channelize their production portfolio?

About Market Industry Reports
Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the calibre of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.

We continue to pioneer state-of-the-art approach in research & analysis that makes complex world simpler to stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence we bring proficient contingency to our clients in the evolving world of technologies, megatrends and industry convergence. We empower and inspire Vanguards to fuel and shape their business to build and grow world-class consumer products.

Contact Us-
Phone: + 91 8956767535

Media Relations Contact

Ajay Rana
+91 8956 767 535

View this press release online at: